Future studies are warranted to explore whether Mer expression and/or activation status in tumor tissues would be correlated with the response of patients with NSCLC harboring EGFR mutation to erlotinib or other EGFR-targeted agents. This evidence concerns the gene EGFR and non-small cell lung carcinoma.